Get the Stockscreener App
3.54
5.60%
-0.21
Humacyte Inc stock is traded at $3.54, with a volume of 1.61M.
It is down -5.60% in the last 24 hours and down -22.37% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$3.75
Open:
$3.8
24h Volume:
1.61M
Relative Volume:
0.40
Market Cap:
$455.49M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-3.3084
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-9.46%
1M Performance:
-22.37%
6M Performance:
-45.29%
1Y Performance:
-16.51%
1-Day Range:
$3.54
$3.82
1-Week Range:
$3.54
$4.04
52-Week Range:
$2.81
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
3.54 | 455.49M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Lost Money on Humacyte, Inc. (HUMA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven? - Yahoo Finance UK
Humacyte stock rallies 19% on FDA RMAT designation - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Humacyte, Inc. to Contact the Firm Today! - ACCESS Newswire
Humacyte moves to test bioengineered vessel in heart surgery - MSN
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights - MSN
LJI Wealth Management LLC Purchases Shares of 185,000 Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
North Carolina biotech weighs demand as breakthrough treatment hits market - The Business Journals
Trilogy Capital Inc. Buys New Holdings in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know - MSN
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bullish Humacyte Insiders Loaded Up On US$803.3k Of Stock - Simply Wall St
Investing in Humacyte Inc (HUMA) Is Getting More Attractive - Knox Daily
Financial Analysis: Humacyte Inc (HUMA)’s Ratios Unveil Key Insights - The Dwinnex
Examining Humacyte Inc (HUMA) more closely is necessary - US Post News
Wealth Effects LLC Buys 57,200 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMAW) Trading Down 1% – What’s Next? - Defense World
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
Humacyte and Pluristyx enhance partnership for diabetes treatment By Investing.com - Investing.com South Africa
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Humacyte, Pluristyx Announce Gene Editing Partnership -January 28, 2025 at 12:05 pm EST - Marketscreener.com
Humacyte and Pluristyx enhance partnership for diabetes treatment - Investing.com India
Humacyte and Pluristyx Announces Gene Editing Partnership to Support BioVascular Pancreas (BVP?) Development Using iPSCs - Marketscreener.com
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs - The Manila Times
Revolutionary Diabetes Breakthrough: Gene-Edited Cell Technology Could End Daily Insulin Injections - StockTitan
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - accessnewswire.com
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2 Firms Want To Co-Lead Humacyte Investor Suit - Law360
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Investors to Inquire about Securities Investigation - ACCESS Newswire
Humacyte: Upside Potential, But I Will Wait For Revenue Trends - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Humacyte, Inc. (HUMA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - ACCESS Newswire
Cantor Fitzgerald Comments on Humacyte FY2025 Earnings - Defense World
Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital - Defense World
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Cantor Fitzgerald Estimates Humacyte FY2025 Earnings - MarketBeat
Humacyte moves to test bioengineered vessel in heart surgery By Investing.com - Investing.com Australia
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law - GlobeNewswire
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire Inc.
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):